Cybin announces psychedelic molecule CYB003’s positive data demonstrating significant advantages over oral psilocybin for the treatment of mental health.
Comparative CYB003 pre-clinical data on Cybin’s deuterated psilocybin analog may have wide-reaching implications for the treatment of major depressive disorder (“MDD”) and alcohol use disorder (“AUD”) with less patient variability, faster onset of action, shorter duration of effect, and improved brain penetration.
View the complete press release here:
Interested in learning more about Cybin? Here’s where to follow Cybin’s latest news:
Subscribe to our Youtube channel: https://www.youtube.com/c/CybinInc
Visit our website: https://cybin.com/
Like us on Facebook: https://www.facebook.com/cybinInc
Follow us on Instagram: https://www.instagram.com/cybininc/
Follow us on Twitter: https://twitter.com/CybinInc